DK3204492T3 - Fremgangsmåde til generering af t-celleforløbere - Google Patents

Fremgangsmåde til generering af t-celleforløbere Download PDF

Info

Publication number
DK3204492T3
DK3204492T3 DK15771979.0T DK15771979T DK3204492T3 DK 3204492 T3 DK3204492 T3 DK 3204492T3 DK 15771979 T DK15771979 T DK 15771979T DK 3204492 T3 DK3204492 T3 DK 3204492T3
Authority
DK
Denmark
Prior art keywords
generating
cell procedures
procedures
cell
Prior art date
Application number
DK15771979.0T
Other languages
English (en)
Inventor
Chantal Lagresle-Peyrou
Salima Hacein-Bey-Abina
Christian Reimann
Chappedelaine Corinne De
Isabelle André
Emmanuelle Six
Marina Cavazzana
Original Assignee
Hopitaux Paris Assist Publique
Fondation Imagine Inst Des Maladies Genetiques
Inst Nat Sante Rech Med
Univ Paris Cite
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hopitaux Paris Assist Publique, Fondation Imagine Inst Des Maladies Genetiques, Inst Nat Sante Rech Med, Univ Paris Cite filed Critical Hopitaux Paris Assist Publique
Application granted granted Critical
Publication of DK3204492T3 publication Critical patent/DK3204492T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/42—Notch; Delta; Jagged; Serrate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1114—T cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/52—Fibronectin; Laminin

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Peptides Or Proteins (AREA)
DK15771979.0T 2014-10-06 2015-10-05 Fremgangsmåde til generering af t-celleforløbere DK3204492T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1459539A FR3026744B1 (fr) 2014-10-06 2014-10-06 Methode de generation de progeniteurs de cellules t
PCT/EP2015/072889 WO2016055396A1 (fr) 2014-10-06 2015-10-05 Méthode de génération de progéniteurs de cellules t

Publications (1)

Publication Number Publication Date
DK3204492T3 true DK3204492T3 (da) 2022-06-07

Family

ID=52102849

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15771979.0T DK3204492T3 (da) 2014-10-06 2015-10-05 Fremgangsmåde til generering af t-celleforløbere

Country Status (11)

Country Link
US (1) US12071635B2 (da)
EP (2) EP3204492B1 (da)
JP (2) JP6898240B2 (da)
CA (1) CA2963756C (da)
DK (1) DK3204492T3 (da)
ES (1) ES2914082T3 (da)
FR (1) FR3026744B1 (da)
HU (1) HUE059468T2 (da)
PL (1) PL3204492T3 (da)
PT (1) PT3204492T (da)
WO (1) WO2016055396A1 (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12076342B2 (en) 2016-04-08 2024-09-03 The Governing Council Of The University Of Toronto Method for generating progenitor t cells from stem and/or progenitor cells and use of same
EP4067482A1 (en) 2017-02-13 2022-10-05 Assistance Publique - Hôpitaux de Paris Method for generating t cells progenitors
WO2019157597A1 (en) * 2018-02-14 2019-08-22 Sunnybrook Research Institute Method for generating cells of the t cell lineage
FR3079239A1 (fr) * 2018-03-23 2019-09-27 Centre National De La Recherche Scientifique Nouvelle methode d’obtention de cellules t a partir de cellules souches pluripotentes, et leurs utilisations
EP3774867A1 (en) * 2018-04-10 2021-02-17 Stichting Sanquin Bloedvoorziening Chimeric notch receptors
AU2021385606B2 (en) 2020-11-30 2026-02-05 Cho Pharma, Inc. Antibody for enrichment of cells
EP4426319A1 (en) 2021-11-04 2024-09-11 APHP (Assistance Publique - Hôpitaux de Paris) Method for generating nk cells
EP4669327A1 (en) 2023-02-22 2025-12-31 Meiragtx Cell Therapies THYMUS REGENERATION PROCESS
KR20260041821A (ko) 2023-07-12 2026-03-27 메이라지티엑스 셀 테라피스 특이적 동형접합성 hla 일배체형을 갖는 세포 뱅크의 바이오뱅크 및 환자 치료를 위한 이의 용도
WO2025219552A1 (en) 2024-04-17 2025-10-23 Assitance Publique Hopitaux De Paris Method for producing t cell progenitors from human pluripotent stem cells
WO2025255678A1 (en) * 2024-06-14 2025-12-18 Stemcell Technologies Canada Inc. Compositions and methods for generating lymphoid lineage cells

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093531A (en) 1997-09-29 2000-07-25 Neurospheres Holdings Ltd. Generation of hematopoietic cells from multipotent neural stem cells
JP2001525176A (ja) 1997-12-04 2001-12-11 デューク・ユニバーシティー Ｃｄ７＋ｃｄ３４−ｌｉｎ−造血細胞を単離し、使用する方法
US8927273B2 (en) * 2003-08-22 2015-01-06 Takara Bio Inc. Process for producing cytotoxic lymphocytes
WO2009097140A1 (en) 2008-01-30 2009-08-06 Memorial Sloan-Kettering Cancer Center Methods for off -the -shelf tumor immunotherapy using allogeneic t-cell precursors
WO2010031006A1 (en) 2008-09-12 2010-03-18 Cryopraxis Criobiologia Ltda. Ischemic tissue cell therapy
WO2010051634A1 (en) 2008-11-07 2010-05-14 Sunnybrook Health Sciences Centre Human progenitor t-cells
US8871510B2 (en) * 2009-12-03 2014-10-28 University Of Utah Research Foundation Methods for generating T lymphocytes from hematopoietic stem cells
US20130095079A1 (en) 2010-04-09 2013-04-18 Fred Hutchinson Cancer Research Center Compositions and methods for providing hematopoietic function without hla matching
WO2013074916A1 (en) 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
EP2788476B1 (en) 2011-12-08 2019-05-22 Fred Hutchinson Cancer Research Center Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
US20150352180A1 (en) * 2013-01-11 2015-12-10 The Trustee Of The University Of Pennsylvania Notch Ligand Bound Biocompatible Substrates And Their Use In Bone Formation
CA2954168C (en) 2013-08-02 2023-09-19 The Regents Of The University Of California Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors
WO2015099134A1 (ja) 2013-12-26 2015-07-02 アストリム株式会社 再構成されたｔ細胞レセプター遺伝子を有する多能性幹細胞由来のｔ前駆細胞を用いる免疫細胞療法
US20170158749A1 (en) 2014-04-23 2017-06-08 Board Of Regents, The University Of Texas System Chimeric antigen receptors (car) and methods for making and using the same
WO2015162211A1 (en) 2014-04-24 2015-10-29 Miltenyi Biotec Gmbh Method for automated generation of genetically modified t cells
US10543257B2 (en) * 2014-09-11 2020-01-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Lentiviral vector for treating hemoglobin disorders

Also Published As

Publication number Publication date
WO2016055396A1 (fr) 2016-04-14
CA2963756A1 (fr) 2016-04-14
ES2914082T3 (es) 2022-06-07
PT3204492T (pt) 2022-05-30
CA2963756C (fr) 2024-01-02
US12071635B2 (en) 2024-08-27
EP3204492B1 (fr) 2022-03-09
FR3026744A1 (fr) 2016-04-08
JP2017531448A (ja) 2017-10-26
ES2914082T8 (es) 2022-06-16
PL3204492T3 (pl) 2022-07-25
FR3026744B1 (fr) 2024-04-19
EP3204492A1 (fr) 2017-08-16
JP2021072779A (ja) 2021-05-13
EP4036224A1 (fr) 2022-08-03
HUE059468T2 (hu) 2022-12-28
US20180208895A1 (en) 2018-07-26
JP6898240B2 (ja) 2021-07-07

Similar Documents

Publication Publication Date Title
HUE049175T2 (hu) Eljárás anti-CD79b immunkonjugátumok alkalmazására
IL249981A0 (en) Method
DK3072835T3 (da) Fremgangsmåde til fremføring
DK3186376T3 (da) Fremgangsmåder til forbedring af cas9-medieret manipulationseffektivitet
DK3294700T3 (da) Fremgangsmåde til fremstilling af limonen-4-ol
DK3789042T3 (da) Fremgangsmåde til fremstilling af anti-her3-antistof-lægemiddelkonjugat
DK3112249T3 (da) System til behandling af boil-off-gas
DK3166537T3 (da) Fremgangsmåde til design af et individuelt tilpasset implantat
DK3359281T3 (da) Fremgangsmåde til udtrækning af CO2
DK3940352T3 (da) Fremgangsmåde til diagnosticering af vægte
DK3122444T3 (da) Fremgangsmåde til fremstilling af membraner
DK3125898T3 (da) Farmakofor til trail-induktion
LT3233813T (lt) Į oksatiaziną panašių junginių gavimo būdai
DK3529233T3 (da) Fremgangsmåde til fremstilling af 3-alkylsulfanyl-2-chlor-n-(1-alkyl-1h-tetrazol-5-yl)-4-trifluoromethyl-benzamider
DK3149717T3 (da) Holder til sikkerhedsindretning
HUE038343T2 (hu) Eljárás forrasztott kapcsolat kialakítására
HUE059468T2 (hu) Módszer T-sejt progenitorok generálására
DK3529262T3 (da) Fremgangsmåder til fremme af t-cellerespons
DK3423714T3 (da) Fremgangsmåde til generering af elektricitet
DK3166855T3 (da) Fremgangsmåde for tilvejebringelse af foldelinjer
DK3367910T3 (da) Fremgangsmåde til anvendelse af en sondeafdækning
DK3274143T3 (da) Fremgangsmåde til fremstilling af lignocellulosematerialer
DK3295941T3 (da) Fremgangsmåde til fremstilling af form a af grapiprant
DK3152191T3 (da) Forbedret fremgangsmåde til fremstilling af duocarmycin-prodrugs
GB201410003D0 (en) Laser device